Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

NCT01484548 | Completed Phase 1 DMC

• 1 other identifier: IDRI-LVVPX-111
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis. The vaccine, identified as LEISH-F3 + GLA-SE, consists of the recombinant two-antigen Leishmania recombinant protein LEISH-F3 together with the adjuvant GLA-SE.

Conditions

Leishmaniasis

Outcome Measures

Primary Outcomes (1)

• Number of patients experiencing adverse events.

  To evaluate the safety and tolerability of 20 μg of LEISH-F3 together with 2 or 5 μg of GLA-SE compared to 20 µg of LEISH-F3 alone following intramuscular administration on Days 0, 28, and 56. The safety assessments will be based on local and systemic reactions, including reported adverse events, changes in laboratory values, and changes in vital signs. The severity and relationship to treatment will be recorded for all adverse events.

  421 days

Secondary Outcomes (1)

• Immunogenicity

  Days 0, 7, 35, 63, 84, and 168.

Study Arms (3)

Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE

EXPERIMENTAL

Low dose of adjuvant.

Biological: LEISH-F3 + GLA-SE

Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE

EXPERIMENTAL

Higher dose of adjuvant.

Biological: LEISH-F3 + GLA-SE

20 ug LEISH-F3 alone

ACTIVE COMPARATOR

20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.

Biological: LEISH-F3 alone

Interventions

LEISH-F3 + GLA-SE BIOLOGICAL

20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE

LEISH-F3 alone BIOLOGICAL

20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.

20 ug LEISH-F3 alone

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Males and females 18 years to 45 years of age.
• Must be in good general health as confirmed by a medical history and physical exam.
• Female subjects of childbearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test on the day of each study injection, must not be breast-feeding, and are required to use one of the following methods of contraception during the first 3 months of the study: hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); abstinence; or bilateral tubal ligation (if no conception post-procedure). These precautions are necessary due to unknown effects that LEISH-F3 + GLA SE or LEISH-F3 alone might have in a fetus or newborn infant.
• The following screening laboratory blood tests must have values within the normal ranges or not clinically significant as determined by the PI and Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, fasting lipid panel, total WBC count, hemoglobin, and platelet count.
• The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
• Negative urine test for recreational drugs and alcohol per Clinical Research Unit standards.
• Urinalysis not clinically significant as determined by the study clinician.
• Must be capable of completing a study diary in English.
• Must give written informed consent, be able and willing to attend all evaluation visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address.

You may not qualify if:

• Subjects who meet ANY of the following criteria will be excluded from the study (ineligible):
• History of possible infection with Leishmania or previous exposure to Leishmania vaccines or experimental products containing GLA-SE.
• Veterans who served in the military in the Middle East (Iran, Iraq), Afghanistan, or any other areas endemic to Leishmania.
• Travelers to, or immigrants from, areas endemic to Leishmania.
• Participation in another experimental protocol or receipt of any investigational products within the past 3 months.
• Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) within the past 6 months.
• Received a blood transfusion within the past 3 months.
• Donated blood products (platelets, whole blood, plasma, etc.) within past 1 month.
• Received any vaccine within past 1 month. Note: No immunizations while on study with the exception of seasonal influenza vaccine which should not be given until 1 month after the third study injection (Day 84).
• History of autoimmune disease or other causes of immunosuppressive states.
• History or evidence of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic, or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
• Rash, tattoos or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
• BMI greater than 30 kg/m2
• Hypertension (systolic greater than 150 or diastolic greater than 95).
• History of significant psychiatric illness with current use of medication.

Sponsors & Collaborators

• Access to Advanced Health Institute (AAHI): lead

Study Sites (1)

Comprehensive Clinical Development NW, Inc.

Tacoma, Washington, 98418, United States

Location

MeSH Terms

Conditions

Leishmaniasis

Condition Hierarchy (Ancestors)

Euglenozoa Infections; Protozoan Infections; Parasitic Diseases; Infections; Skin Diseases, Parasitic; Vector Borne Diseases; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Franco Piazza, MD, MPH

  Access to Advanced Health Institute (AAHI)

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 29, 2011
• First Posted: December 2, 2011
• Study Start: January 1, 2012
• Primary Completion: August 1, 2012
• Study Completion: May 1, 2013
• Last Updated: February 26, 2014

Record last verified: 2014-02

Locations

US (1)